Heracleum humile
Heracleum humile · Accepted scientific name
Scientific literature: Very Sparse (3 studies) · ★☆☆☆☆
Heracleum humile is a botanical species currently being investigated for its significant therapeutic potential in pharmacological research. Recent studies have focused on evaluating its anticancer, antimicrobial, and antioxidant activities to understand its medicinal value. Scientific investigations utilize various preparations, including ethyl acetate, methanol, and water extracts, to isolate its bioactive components. These studies specifically highlight the presence of flavonoids, which are believed to drive the plant's biological effects. Furthermore, the efficacy of these extracts is being rigorously tested against MDA-MB-231 cell lines to assess their impact on cancer cell progression.
- Synonyms
- Pastinaca Humilis · Heracleum Massyciticum
- Common names
- Not available
- Family
- Apiaceae
- Distribution
- Africa
- Plant Parts
- Not available
Classification
Common Names
Heracleum humile is a distinctive plant known by its Hebrew common name, הרקליאון נמוך. This species belongs to the impressive carrot family, often recognized by its unique structural characteristics. While it shares a lineage with many larger relatives, this particular variety maintains a more modest stature. Understanding its botanical identity helps enthusiasts appreciate the diversity found within its genus. By learning its local name, gardeners and botanists can more easily identify it in the wild.
Sources: Catalogue of Life (COL)
Synonyms
Heracleum humile is a botanical subject characterized by its complex taxonomic history and various naming conventions. Within scientific literature, this plant is frequently identified by the synonym Heracleum massyciticum. Researchers also encounter it under the alternative designation of Pastinaca humilis in different classification contexts. These overlapping names highlight the evolving nature of plant nomenclature and the shifts in botanical categorization. Understanding these relationships is essential for accurately identifying the species across diverse herbarium records and studies.
Sources: The World Checklist of Vascular Plants (WCVP)
Taxonomy
Heracleum humile is a unique botanical specimen belonging to the kingdom Plantae. Within this vast kingdom, it is classified under the class Equisetopsida. Its evolutionary lineage places it specifically in the order Apiales. Furthermore, the plant is a member of the Apiaceae family, a group known for its distinctive flowering structures. Ultimately, this species is defined by its placement within the genus Heracleum.
| Rank | Classification |
|---|---|
| Kingdom | Plantae |
| Phylum | Streptophyta |
| Class | Equisetopsida |
| Subclass | Magnoliidae |
| Order | Apiales |
| Family | Apiaceae |
| Genus | Heracleum |
Sources: The World Checklist of Vascular Plants (WCVP)
Distribution
Geographic Regions
Heracleum humile is a botanical species characterized by a distinct geographical footprint across several continents. Its presence is well-documented within the Asia-Temperate regions, specifically spanning the landscapes of Western Asia from Lebanon to Syria. The plant also maintains a significant distribution throughout Türkiye, further establishing its reach in the Middle East. Moving westward, the species extends its range into Europe, where it can be found throughout Southeastern Europe. Notably, Greece serves as a key location within its Mediterranean habitat.
Sources: The World Checklist of Vascular Plants (WCVP)
Identification
Biological Activities
Heracleum humile shows significant promise as a source for developing natural, multifunctional pharmaceuticals. Recent studies utilizing ultrasound-assisted extraction have revealed that the plant contains high levels of flavonoids and phenolic acids. These bioactive compounds contribute to the plant's notable antioxidant and antimicrobial properties. Furthermore, the extracts have demonstrated effective anticancer activity, particularly through cytotoxic effects on specific cancer cell lines. Ultimately, these findings suggest that Heracleum humile could serve as a valuable candidate for future medicinal advancements.
Compounds
Heracleum humile serves as a promising source for developing new natural medicines due to its diverse pharmacological properties. Recent research utilizing ultrasound-assisted extraction has revealed that the plant's extracts contain a rich profile of bioactive compounds. Specifically, all extracts of the species were found to contain mainly flavonoids, alongside phenolic acids and their various derivatives. These flavonoids are well-known for possessing essential biological activities, including antioxidant, anti-inflammatory, and anticancer effects. Ultimately, these findings suggest that the plant could be a valuable candidate in the creation of novel, multifunctional plant-derived pharmaceuticals.
Conditions
Heracleum humile demonstrates significant biological potential through its various extracts. The plant exhibits weak antibacterial activity when applied to tested bacterial species. Regarding anticancer properties, the ethyl acetate extract shows strong cytotoxic activity against MDA-MB-231 cell lines. Furthermore, the extracts effectively treat MCF-7 cell lines, showing notable results during the MTT test. These combined effects highlight the plant's ability to interact with both bacterial and cancer cell targets.
Preparations
Heracleum humile is prepared as an ethyl acetate extract, a methanol extract, and a water extract through an ultrasonic-assisted extraction process. These specific preparations were utilized to evaluate the various biological and pharmacological properties of the plant. Researchers specifically focused on these three types of extracts to investigate their antibacterial and cytotoxic activities. By producing the ethyl acetate, methanol, and water extracts, the study was able to identify key bioactive compounds like flavonoids and phenolic acids. Consequently, these different preparations of Heracleum humile serve as essential components for developing novel plant-derived pharmaceuticals.